Malignant peripheral nerve sheath tumour with rhabdomyoblastic and glandular differentiation: immunohistochemical features

Abstract

Brief reports 2 8 7 plasma cells. The abundant free eosinophilic material also stained for kappa light chain. It was concluded that the nodules represented a plasmacytoma, producing abundant extracellular immunoglobulin which was being ingested by macrophages in particular, but also by alveolar and bronchiolar epithelial cells. Nine years later the patient is well and has no evidence of recurrence or of myelomatosis: he has no abnormal serum or urine immunoglobulin and no skeletal abnormalities: total serum protein is 79.8 g/1 and there are no abnormal fractions. DiscussionCrystalline cytoplasmic inclusions have been described in both normal and neoplastic plasma cells, in macrophages in both myelomatosis and solitary plasmacytomas and in renal epithelium in myelomat~sis~-~. The uptake of immunoglobulin by airway epithelial cells, demonstrated in this case, is unusual but not surprising as some of these cells normally process immunoglobulin A, adding secretory piece as this immunoglobulin crosses the epitheliumb. What defeated the initial diagnostic attempts in this case was the sparsity of plasma cells and the marked local deposition of their secretory product. Electronmicroscopy suggested the correct diagnosis which was confirmed by immunocytochemistry. Addis BJ. Lymphoproliferative disease. In Corrin B ed. The Lungs. Edinburgh: Churchill Livingston. 1990: 328. Addis BJ. Isaacson P. Billings JA. Plasmacytoma of lymph nodes. Cancer 1980: 46; 340-346. Mullen B, Chalvardjian A. Crystalline tissue deposits in a case of multiple myeloma. Arch. Pathol. Lab. Med. 1981: 105; 94-97. Chejfec G. Natarelli J, Gould VE. 'Myeloma lung'--a previously unreported complication of multiple myeloma. Hum. Pathol. 1983: Yamamoto T, Hishida A. Honda N. Ito I, Shirasawa H. Nagase M. Crystal-storing histiocytosis and crystalline tissue deposition in multiple myeloma. Arch. Pathol. Lab. Med. 1991: 115: 351-354. Goodman JR, Link DW. Brown WR. Nakane PK. Ultrastructural evidence of transport of secretory IgA across bronchial epithelium. Am. Rev. Resp. Dis.

Malignant Nerve-Sheath Tumor with Divergent and Glandular Differentiation in a Dog: A Case Report

“…3,4,6 A small percentage of these tumors (10%), both benign and malignant, are characterized by divergent differentiation. 1,2,4,8,[10][11][12] Rhabdomyosarcoma, osteosarcoma, chondrosarcoma, angiosarcoma, and melanoma are common mesenchymal differentiations, myosarcoma being more common than the others. 5,11,12 Glandular and epithelial differentiation are extremely rare.…”

“…5 Both mesenchymal and epithelial types of differentiation can be benign or malignant. 1,2,4,[10][11][12] Nerve sheath-tumor with glandular differentiation was first described by Garre in 1892. 7 A combination of different types of sarcoma alone or in combination with epithelial components has also been reported.…”

“…7 A combination of different types of sarcoma alone or in combination with epithelial components has also been reported. 5,10,11 Divergent differentiation of malignant nerve-sheath tumor has been associated with a poor prognosis. 11,12 Although cranial nerve-sheath tumors in dogs is uncommon, a search of the English veterinary literature for the past 20 years revealed no report of nerve-sheath tumor with divergent differentiation except for one report of two dogs with malignant Schwannoma with melanotic differentiation.…”

“…These findings are similar to those in human medicine. 4,5,10 It is relatively common to find metaplastic changes in nerve-sheath tumors, both benign and malignant. The most common secondary elements are cartilage and bone.…”

Pediatric Malignant Peripheral Nerve Sheath Tumour of the Radial Nerve

“…Actin positivity in these lesions may represent the early stage of cellular differentiation or invasion into the surrounding muscle tissue, but is also described in patients whose tumours have rhabdomyoplastic components. [11][12][13] Significant Leu7 positivity is an expected finding with myelin-associated glycoprotein as the antibody target, although cell surface reactivity with natural killer cells is also well known. Cytokeratin AE1.3 is commonly used to screen for epithelial components of tumour, particularly in poorly differentiated malignant lesions, although reactivity against both glial and non-glial tumours that express GFAP is well known and consequently may have limited value in discerning the malignant potential of this subgroup of lesions.…”